Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

PMID:
29955135
2.

National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation.

Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S.

Oral Oncol. 2018 Jul;82:122-130. doi: 10.1016/j.oraloncology.2018.02.010. Epub 2018 May 26.

PMID:
29909886
3.

Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database.

Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL.

Head Neck. 2018 Jul;40(7):1343-1355. doi: 10.1002/hed.24984. Epub 2018 May 13.

PMID:
29756412
4.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

PMID:
29752322
5.

Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.

Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z.

Oral Oncol. 2018 Apr;79:64-70. doi: 10.1016/j.oraloncology.2018.02.017. Epub 2018 Mar 8.

PMID:
29598952
6.

Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Bhatia AK, Burtness BA, Decker RH.

J Clin Oncol. 2018 May 1;36(13):1269-1271. doi: 10.1200/JCO.2018.77.7987. Epub 2018 Mar 16. No abstract available.

PMID:
29547345
7.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

8.

Response.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2018 Apr 1;110(4):433-434. doi: 10.1093/jnci/djx230. No abstract available.

PMID:
29121329
9.

The tumor genome in human immunodeficiency virus-related head and neck cancer: Exploitable targets?

Burtness B.

Cancer. 2018 Jan 1;124(1):14-17. doi: 10.1002/cncr.31059. Epub 2017 Oct 20. No abstract available.

PMID:
29053184
10.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

11.

Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.

Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N.

Clin Cancer Res. 2017 Dec 1;23(23):7276-7287. doi: 10.1158/1078-0432.CCR-17-1438. Epub 2017 Sep 15.

PMID:
28916527
12.

Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Bhatia A, Burtness B.

Cancers (Basel). 2017 Aug 31;9(9). pii: E113. doi: 10.3390/cancers9090113. Review.

13.

Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).

Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ.

Cancer. 2017 Dec 1;123(23):4653-4662. doi: 10.1002/cncr.30920. Epub 2017 Aug 7.

PMID:
28786105
14.

Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck.

Parameswaran J, Burtness B.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):969-973. doi: 10.1016/j.ijrobp.2017.03.003. Epub 2017 Jul 10. No abstract available.

PMID:
28721906
15.

Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification.

Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ.

Ear Nose Throat J. 2017 Jul;96(7):E12-E18.

PMID:
28719713
16.

Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment.

Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S.

Oral Oncol. 2017 Aug;71:129-137. doi: 10.1016/j.oraloncology.2017.06.013. Epub 2017 Jun 23.

PMID:
28688680
17.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

PMID:
28596256
18.

Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.

Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx042.

PMID:
28521361
19.

Reply to A. Garden et al.

Marur S, Li S, Cmelak A, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1970-1971. doi: 10.1200/JCO.2017.72.8279. Epub 2017 Apr 21. No abstract available.

PMID:
28430530
20.

Purpose of Induction Chemotherapy in E1308 and Importance of Patient-Reported Outcomes in Deintensification Trials.

Marur S, Cmelak AJ, Burtness B.

J Clin Oncol. 2017 Jun 10;35(17):1968-1969. doi: 10.1200/JCO.2017.72.2918. Epub 2017 Apr 21. No abstract available.

PMID:
28430529
21.

The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.

Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA.

Pract Radiat Oncol. 2017 Sep - Oct;7(5):e317-e321. doi: 10.1016/j.prro.2017.02.004. Epub 2017 Feb 16.

PMID:
28356201
22.

The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA.

Cancer. 2017 Jul 15;123(14):2762-2772. doi: 10.1002/cncr.30598. Epub 2017 Mar 21.

23.

TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.

Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N.

Cancer. 2017 May 15;123(10):1778-1790. doi: 10.1002/cncr.30570. Epub 2017 Mar 13.

24.

Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study.

Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z.

JAMA Oncol. 2017 Aug 1;3(8):1107-1111. doi: 10.1001/jamaoncol.2016.5769.

25.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

26.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

27.

Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma.

Baxi SS, Dunn LA, Burtness BA.

Oral Oncol. 2016 Nov;62:147-148. doi: 10.1016/j.oraloncology.2016.10.007. Epub 2016 Oct 21. No abstract available.

PMID:
27776933
28.

Treatment de-intensification strategies for head and neck cancer.

Kelly JR, Husain ZA, Burtness B.

Eur J Cancer. 2016 Nov;68:125-133. doi: 10.1016/j.ejca.2016.09.006. Epub 2016 Oct 15. Review.

29.

A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.

Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA.

JAMA Oncol. 2017 Mar 1;3(3):358-365. doi: 10.1001/jamaoncol.2016.4581.

PMID:
27737449
30.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.

PMID:
27646946
31.

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma.

Psyrri A, Rampias T, Burtness B.

JAMA Oncol. 2017 Jan 1;3(1):125. doi: 10.1001/jamaoncol.2016.3409. No abstract available.

PMID:
27607105
32.

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Oct;15(10):2486-2497. Epub 2016 Aug 9.

33.

Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.

Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL.

Cancer. 2016 Dec 1;122(23):3624-3631. doi: 10.1002/cncr.30227. Epub 2016 Aug 1.

34.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.

35.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ.

Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.

PMID:
27247226
36.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ.

Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.

PMID:
27157491
37.

Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base.

Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL.

Cancer. 2016 Jun 15;122(12):1853-60. doi: 10.1002/cncr.29962. Epub 2016 Mar 28.

38.

Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA.

Am J Clin Oncol. 2017 Aug;40(4):393-398. doi: 10.1097/COC.0000000000000171.

PMID:
26986978
39.

Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Husain ZA, Burtness BA, Decker RH.

J Clin Oncol. 2016 Feb 10;34(5):396-8. doi: 10.1200/JCO.2015.64.7586. Epub 2015 Dec 7. No abstract available.

PMID:
26644528
40.

National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database.

Schwam ZG, Burtness B, Yarbrough WG, Mehra S, Husain Z, Judson BL.

Cancer Med. 2015 Dec;4(12):1828-35. doi: 10.1002/cam4.546. Epub 2015 Oct 16.

41.

Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Bhatia A, Burtness B.

J Clin Oncol. 2015 Oct 10;33(29):3243-50. doi: 10.1200/JCO.2015.61.2358. Epub 2015 Sep 8. Review.

42.

Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer.

Burtness B.

J Clin Oncol. 2015 Nov 20;33(33):3845-6. doi: 10.1200/JCO.2015.62.8487. Epub 2015 Aug 17. No abstract available.

PMID:
26282638
43.

Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.

Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R.

Oncotarget. 2015 Aug 7;6(22):18863-74.

44.

Head and Neck Cancers, Version 1.2015.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M.

J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856.

45.

EGFR-directed antibodies increase the risk of severe infection in cancer patients.

Altan M, Burtness B.

BMC Med. 2015 Feb 20;13:37. doi: 10.1186/s12916-015-0276-9.

46.

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.

Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A.

Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.

47.

Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.

Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE.

Ann Thorac Surg. 2015 Jan;99(1):270-6. doi: 10.1016/j.athoracsur.2014.08.033. Epub 2014 Nov 18.

49.

On mentorship: lessons from my father.

Burtness B.

J Natl Compr Canc Netw. 2014 Nov;12(11):1651-2. No abstract available.

PMID:
25361809
50.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.

Supplemental Content

Loading ...
Support Center